行情

VCEL

VCEL

Vericel
NASDAQ

实时行情|Nasdaq Last Sale

18.65
+0.11
+0.59%
盘后: 18.65 0 0.00% 16:00 11/15 EST
开盘
18.74
昨收
18.54
最高
18.81
最低
18.52
成交量
28.74万
成交额
--
52周最高
21.01
52周最低
13.40
市值
8.34亿
市盈率(TTM)
-58.2085
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VCEL 新闻

  • 关厂风波肆起、显示屏遭质疑:三星能否靠5G绝地求生
  • 蓝鲸TMT.23分钟前
  • 约翰逊承诺结束令经济“陷入瘫痪”的英退不确定性
  • 新浪财经综合.33分钟前
  • 一周财经日历丨美团、拼多多财报出炉,阿里或于周三定价
  • 华盛通.39分钟前
  • 蔚来宣布奉玮出任CFO 后者曾任中金研究部董事总经理
  • 新浪科技.1小时前

更多

所属板块

制药
+1.37%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

VCEL 简况

Vericel Corporation is an integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of cellular therapies for use in the treatment of specific diseases.. Its autologous cell therapy products include Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.
展开

Webull提供Vericel Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。